{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:12:58Z","timestamp":1787508778257,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100032288","name":"IL-YANG Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032288","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Institute of Pharmaceutical Sciences of Seoul National Univeristy"},{"name":"Brain Korea 21 Program"},{"name":"Research Institute of Pharmaceutical Sciences of Seoul National University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10637-026-01610-6","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:27:44Z","timestamp":1774621664000},"page":"187-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical pharmacokinetic characteristics and the food effect of radotinib"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1543-3783","authenticated-orcid":false,"given":"Yerin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2433-4228","authenticated-orcid":false,"given":"Jiwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6818-5226","authenticated-orcid":false,"given":"Minseo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7227-9551","authenticated-orcid":false,"given":"Jae Soo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4395-9938","authenticated-orcid":false,"given":"Min Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-8323","authenticated-orcid":false,"given":"Jangik I.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"6","key":"1610_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou T, Medeiros LJ, Hu S (2018) Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep 13(6):435\u2013445. https:\/\/doi.org\/10.1007\/s11899-018-0474-6","journal-title":"Curr Hematol Malig Rep"},{"key":"1610_CR2","unstructured":"Eden RE, Coviello JM (2023) Chronic myelogenous leukemia. StatPearls, Florida"},{"issue":"5405","key":"1610_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290\u2013293. https:\/\/doi.org\/10.1038\/243290a0","journal-title":"Nature"},{"issue":"11","key":"1610_CR4","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H (2024) Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol 99(11):2191\u20132212. https:\/\/doi.org\/10.1002\/ajh.27443","journal-title":"Am J Hematol"},{"issue":"1","key":"1610_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E (2018) Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol 11(1). https:\/\/doi.org\/10.1186\/s13045-018-0624-2","journal-title":"J Hematol Oncol"},{"key":"1610_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2024.100195","volume":"23","author":"R Kumar","year":"2024","unstructured":"Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P, Pal S, Sabarwal A (2024) Recent developments in receptor tyrosine kinase inhibitors: a promising mainstay in targeted cancer therapy. Med Drug Discov 23. https:\/\/doi.org\/10.1016\/j.medidd.2024.100195","journal-title":"Med Drug Discov"},{"issue":"5","key":"1610_CR7","first-page":"1517","volume":"94","author":"RT Silver","year":"1999","unstructured":"Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94(5):1517\u20131536","journal-title":"Blood"},{"key":"1610_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/JBM.S382090","volume":"14","author":"I Rinaldi","year":"2023","unstructured":"Rinaldi I, Winston K (2023) Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review. J Blood Med 14:261\u2013277. https:\/\/doi.org\/10.2147\/JBM.S382090","journal-title":"J Blood Med"},{"issue":"24","key":"1610_CR9","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851\u20132857. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866","journal-title":"J Clin Oncol"},{"issue":"5","key":"1610_CR10","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186-93. https:\/\/doi.org\/10.1016\/S2352-3026(15)00048-4","journal-title":"Lancet Haematol"},{"issue":"23","key":"1610_CR11","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","volume":"23","author":"JY Kwak","year":"2017","unstructured":"Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW (2017) Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Cancer Res 23(23):7180\u20137188. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0957","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1610_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0031-6997(24)01340-1","volume":"49","author":"JH Lin","year":"1997","unstructured":"Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49(4):403\u2013449","journal-title":"Pharmacol Rev"},{"issue":"5","key":"1610_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrclinonc.2014.40","volume":"11","author":"RH Mathijssen","year":"2014","unstructured":"Mathijssen RH, Sparreboom A, Verweij J (2014) Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11(5):272\u2013281. https:\/\/doi.org\/10.1038\/nrclinonc.2014.40","journal-title":"Nat Rev Clin Oncol"},{"key":"1610_CR14","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies. https:\/\/www.fda.gov\/media\/70945\/download Accessed 01 Nov 2025."},{"issue":"3","key":"1610_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2165\/00003088-199937030-00003","volume":"37","author":"BN Singh","year":"1999","unstructured":"Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37(3):213\u2013255. https:\/\/doi.org\/10.2165\/00003088-199937030-00003","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1610_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070672","volume":"12","author":"L Cheng","year":"2020","unstructured":"Cheng L, Wong H (2020) Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool. Pharmaceutics 12(7). https:\/\/doi.org\/10.3390\/pharmaceutics12070672","journal-title":"Pharmaceutics"},{"issue":"8","key":"1610_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/j.1552-4604.1995.tb04117.x","volume":"35","author":"H Boxenbaum","year":"1995","unstructured":"Boxenbaum H, Battle M (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35(8):763\u2013766. https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04117.x","journal-title":"J Clin Pharmacol"},{"key":"1610_CR18","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research (2018) Guidance for industry: bioanalytical method validation. https:\/\/www.fda.gov\/media\/70858\/download Accessed 11 Nov 2025."},{"key":"1610_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.eplepsyres.2016.10.020","volume":"129","author":"BE Gidal","year":"2017","unstructured":"Gidal BE, Clark AM, Anders B, Gilliam F (2017) The application of half-life in clinical decision making: comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. Epilepsy Res 129:26\u201332. https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.10.020","journal-title":"Epilepsy Res"},{"issue":"1","key":"1610_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/FTD.0000000000001270","volume":"47","author":"JD Momper","year":"2025","unstructured":"Momper JD, Venkataramanan R, Jantz AS, Cibrik DM, Birdwell K, Nguyen T, Masters BM, Patel SJ (2025) Evaluation of effective half-life and its impact on time to steady state for oral meltdose tacrolimus (LCPT) in de novo kidney transplant recipients. Ther Drug Monit 47(1):169\u2013173. https:\/\/doi.org\/10.1097\/FTD.0000000000001270","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2141.2010.08245.x","volume":"150","author":"FP Santos","year":"2010","unstructured":"Santos FP, Kantarjian H, Fava C, O\u2019Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J (2010) Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 150(3):303\u201312. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08245.x","journal-title":"Br J Haematol"},{"issue":"8","key":"1610_CR22","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3109\/10428194.2015.1113278","volume":"57","author":"H Noh","year":"2016","unstructured":"Noh H, Park MS, Kim SH, Oh SJ, Zang DY, Park HL, Cho DJ, Kim DW, Lee JI (2016) Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. Leuk Lymphoma 57(8):1856\u20131864. https:\/\/doi.org\/10.3109\/10428194.2015.1113278","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1610_CR23","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/cam4.1436","volume":"7","author":"H Noh","year":"2018","unstructured":"Noh H, Jung SY, Kwak JY, Kim SH, Oh SJ, Zang DY, Lee S, Park HL, Jo DJ, Shin JS, Do YR, Kim DW, Lee JI (2018) Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. Cancer Med 7(5):1766\u20131773. https:\/\/doi.org\/10.1002\/cam4.1436","journal-title":"Cancer Med"},{"key":"1610_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ph18111705","author":"M Kang","year":"2025","unstructured":"Kang M, Kim J, Lee Y, Shin JS, Park MS, Jiang Q, Chung EK, Lee JI (2025) Population pharmacokinetics of radotinib in healthy volunteers and patients with chronic myeloid leukemia. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph18111705","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1610_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.v99.2.713","volume":"99","author":"HG J\u00f8rgensen","year":"2002","unstructured":"J\u00f8rgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD (2002) Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 99(2):713\u2013715. https:\/\/doi.org\/10.1182\/blood.v99.2.713","journal-title":"Blood"},{"issue":"2","key":"1610_CR26","first-page":"625","volume":"9","author":"C Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D\u2019Incalci M (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9(2):625\u201332","journal-title":"Clin Cancer Res"},{"issue":"22","key":"1610_CR27","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/hematology.2020006911","volume":"136","author":"J Cortes","year":"2020","unstructured":"Cortes J (2020) How to manage CML patients with comorbidities. Blood 136(22):2507\u20132512. https:\/\/doi.org\/10.1182\/hematology.2020006911","journal-title":"Blood"},{"key":"1610_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611497","volume":"30","author":"P Batar","year":"2024","unstructured":"Batar P, Alizadeh H, Rokszin G, Abonyi-Toth Z, Demeter J (2024) Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary. Pathol Oncol Res 30. https:\/\/doi.org\/10.3389\/pore.2024.1611497","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/j.clml.2018.05.001","volume":"18","author":"J Gora-Tybor","year":"2018","unstructured":"Gora-Tybor J, Sacha T, W\u0105c\u0142aw J, Niesiob\u0119dzka-Kr\u0119\u017cel J, Grzybowska-Izydorczyk O, M\u0119dra\u015b E, Dere\u0144-Wagemann I, Patkowska E, Sefery\u0144ska I, Lewandowski K, Wache A, Blajer-Olszewska B, W\u0105tek M, Kotwica-Mojzych K, Wasilewska E, Warzocha K, Jamroziak K (2018) Comorbidity burden and use of concomitant medications at CML diagnosis: a retrospective analysis of 527 patients from the Polish Adult Leukemia Group Registry. Clin Lymphoma Myeloma Leuk 18(7):e283\u2013e285. https:\/\/doi.org\/10.1016\/j.clml.2018.05.001","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1610_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M, Sala-Torra O, Radich JP, Passegu\u00e9 E (2011) IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20(5):661\u2013673. https:\/\/doi.org\/10.1016\/j.ccr.2011.10.012","journal-title":"Cancer Cell"},{"issue":"6","key":"1610_CR31","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/leu.2016.34","volume":"30","author":"E Nievergall","year":"2016","unstructured":"Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL (2016) TGF-alpha and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia 30(6):1263\u20131272. https:\/\/doi.org\/10.1038\/leu.2016.34","journal-title":"Leukemia"},{"issue":"6","key":"1610_CR32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.drudis.2016.03.002","volume":"21","author":"AE Willemsen","year":"2016","unstructured":"Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP (2016) Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today 21(6):962\u201376. https:\/\/doi.org\/10.1016\/j.drudis.2016.03.002","journal-title":"Drug Discov Today"},{"key":"1610_CR33","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2020) Guidance for industry: safety testing of drug metabolites. https:\/\/www.fda.gov\/media\/72279\/download Accessed 20 Nov 2025."},{"issue":"2","key":"1610_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00280-022-04454-y","volume":"90","author":"YH Chien","year":"2022","unstructured":"Chien YH, W\u00fcrthwein G, Zubiaur P, Posocco B, Pena M\u00c1, Borobia AM, Gagno S, Abad-Santos F, Hempel G (2022) Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg. Cancer Chemother Pharmacol 90(2):125\u2013136. https:\/\/doi.org\/10.1007\/s00280-022-04454-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1610_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.890","volume":"9","author":"O Olafuyi","year":"2021","unstructured":"Olafuyi O, Parekh N, Wright J, Koenig J (2021) Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? Pharmacol Res Perspect 9(6). https:\/\/doi.org\/10.1002\/prp2.890","journal-title":"Pharmacol Res Perspect"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01610-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01610-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01610-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:41:14Z","timestamp":1785498074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01610-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01610-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review boards (IRBs) of Severance Hospital (IRB number: 4\u20132024-0489) and Peking University People\u2019s Hospital (IRB number: 2018PHA053).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent before the start of study procedure.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yerin Lee, Jiwon Kim, Minseo Kang, Jiwon Han and Jangik I. Lee have received research funding from IL-YANG Pharmaceutical Co., Ltd. Min Soo Park and Qian Jiang received grant from IL-YANG Pharmaceutical Co., Ltd. for conducting Phase 1 or 3 clinical trial as principal investigators. Na Yun Kim and Jae Soo Shin are employed by IL-YANG Pharmaceutical Co., Ltd.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}